Analysts Set Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Target Price at $82.29

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) have been assigned an average rating of “Moderate Buy” from the nine analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $87.00.

TARS has been the topic of several recent analyst reports. Barclays initiated coverage on Tarsus Pharmaceuticals in a report on Monday, December 8th. They set an “overweight” rating and a $100.00 target price on the stock. Oppenheimer boosted their price objective on Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday. The Goldman Sachs Group restated a “neutral” rating and issued a $68.00 price objective on shares of Tarsus Pharmaceuticals in a report on Thursday, February 5th. Zacks Research raised Tarsus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Friday, January 23rd. Finally, Wall Street Zen upgraded shares of Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th.

Insider Buying and Selling

In other news, CEO Bobak R. Azamian sold 6,000 shares of the stock in a transaction on Wednesday, December 24th. The stock was sold at an average price of $82.51, for a total transaction of $495,060.00. Following the completion of the sale, the chief executive officer owned 857,991 shares in the company, valued at approximately $70,792,837.41. This represents a 0.69% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Dianne C. Whitfield sold 7,397 shares of the firm’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $80.10, for a total value of $592,499.70. Following the sale, the insider directly owned 38,958 shares of the company’s stock, valued at approximately $3,120,535.80. This represents a 15.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 8.97% of the stock is owned by insiders.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Comerica Bank raised its holdings in Tarsus Pharmaceuticals by 470.0% during the 4th quarter. Comerica Bank now owns 855 shares of the company’s stock worth $70,000 after buying an additional 705 shares during the period. Truvestments Capital LLC increased its position in shares of Tarsus Pharmaceuticals by 106.1% in the fourth quarter. Truvestments Capital LLC now owns 909 shares of the company’s stock worth $74,000 after acquiring an additional 468 shares in the last quarter. Leonteq Securities AG acquired a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter valued at approximately $164,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Tarsus Pharmaceuticals by 26.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,063 shares of the company’s stock valued at $169,000 after acquiring an additional 431 shares during the period. Finally, Mackenzie Financial Corp purchased a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter valued at approximately $202,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

Tarsus Pharmaceuticals News Summary

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Oppenheimer raised its price target materially and reiterated a positive stance (Outperform), which supports upside expectations for the shares. Oppenheimer Raises PT
• Positive Sentiment: Guggenheim raised its price target on TARS to $90 and maintained a Buy rating, providing additional analyst-level backing for further gains. Guggenheim PT $90
• Positive Sentiment: Tarsus announced management will participate in upcoming investor conferences—this increases management access to investors and can help sustain the re-rating momentum if management delivers encouraging updates. Investor Conferences
• Neutral Sentiment: A market commentary questioned whether Tarsus has been re-rated too cautiously following XDEMVY adoption headlines; this article frames debate about valuation vs execution but does not add hard fundamentals. Market Rerate Analysis
• Negative Sentiment: HC Wainwright trimmed multiple near-term and multi-year EPS forecasts in its Feb. 24 research note — lowering Q1 2026 to about ($0.42) (from $0.05), Q2 to ~($0.17) (from $0.09), Q3 to ~($0.07) (from $0.18), and cutting Q4/QFY and FY2027–FY2029 targets (e.g., FY2027 to $2.33 from $2.90, FY2028 to $3.10 from $4.26, FY2029 to $4.68 from $5.87). These downward revisions increase short-term earnings uncertainty and weigh on fundamental expectations.

Tarsus Pharmaceuticals Stock Performance

TARS stock opened at $75.87 on Friday. The company has a 50-day simple moving average of $72.12 and a 200 day simple moving average of $68.43. The company has a market capitalization of $3.23 billion, a P/E ratio of -46.83, a PEG ratio of 1.05 and a beta of 0.57. The company has a quick ratio of 4.25, a current ratio of 3.85 and a debt-to-equity ratio of 0.21. Tarsus Pharmaceuticals has a fifty-two week low of $38.51 and a fifty-two week high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings results on Monday, February 23rd. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The company had revenue of $151.67 million for the quarter, compared to the consensus estimate of $144.56 million. Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%. Sell-side analysts predict that Tarsus Pharmaceuticals will post -3.17 earnings per share for the current fiscal year.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.